Effect of blood contamination of cerebrospinal fluid on amino acids, biogenic amines, pterins and vitamins
Por:
Batllori-Tragant M, Casado-Rio M, Sierra-March C, Salgado MDC, Marti-Sanchez L, Maynou-Fernández J, Fernandez-Isern G, Garcia-Cazorla A, Ormazabal-Herrero A, Molero M and Artuch-Iriberri R
Publicada:
14 nov 2019
Ahead of Print:
14 nov 2019
Resumen:
Background Cerebrospinal fluid (CSF) metabolomic investigations are a powerful tool for studying neurometabolic diseases. We aimed to assess the effect of CSF contamination with blood on the concentrations of selected biomarkers. Methods CSF samples were spiked in duplicate with increasing volumes of whole blood under two conditions: (A) pooled CSF spiked with fresh whole blood and frozen to cause red blood cell (RBC) lysis; (B) pooled CSF spiked with fresh blood and centrifuged (the supernatant with no RBCs was frozen until the moment of analysis). CSF concentrations of amino acids, biogenic amines, pterins, and vitamins were analysed by HPLC coupled with tandem mass spectrometry, electrochemical and fluorescence detection. Results Aspartate, glutamate, taurine, ornithine, glycine, citrulline, pyridoxal 5 '-phosphate, 5-methyltetrahydrofolate, and thiamine showed higher values when RBCs were lysed when compared with those of CSF with no RBC, while arginine, 5-hydroxyindoleacetic and homovanillic acids showed lower values. When RBCs were removed from CSF, only some amino acids, thiamine and pyridoxal 5 '-phosphate showed moderately higher values when compared with the non-spiked CSF sample. Conclusions CSF-targeted metabolomic analysis is feasible even when substantial RBC contamination of CSF has occurred since CSF centrifugation to remove RBC prior to freezing eliminated most of the interferences observed.
Filiaciones:
Batllori-Tragant M:
Clinical Biochemistry Department, Hospital Sant Joan de Déu, Barcelona, Spain
Casado-Rio M:
Clinical Biochemistry Department, Hospital Sant Joan de Déu, Barcelona, Spain
CIBERER-Instituto de Salud Carlos III, Barcelona, Spain
Sierra-March C:
Clinical Biochemistry Department, Hospital Sant Joan de Déu, Barcelona, Spain
Salgado MDC:
Clinical Biochemistry Department, Hospital Sant Joan de Déu, Barcelona, Spain
Marti-Sanchez L:
Clinical Biochemistry Department, Hospital Sant Joan de Déu, Barcelona, Spain
Maynou-Fernández J:
Molecular Genetics, Hospital Sant Joan de Déu, Barcelona, Spain
Fernandez-Isern G:
Molecular Genetics, Hospital Sant Joan de Déu, Barcelona, Spain
Garcia-Cazorla A:
Pediatric Neurology Department, Institut de Recerca Sant Joan de Déu, Barcelona, Spain
CIBERER-Instituto de Salud Carlos III, Barcelona, Spain
Ormazabal-Herrero A:
Clinical Biochemistry Department, Hospital Sant Joan de Déu, Barcelona, Spain
CIBERER-Instituto de Salud Carlos III, Barcelona, Spain
Molero M:
Clinical Biochemistry Department, Hospital Sant Joan de Déu, Barcelona, Spain.
Artuch-Iriberri R:
Clinical Biochemistry Department, Hospital Sant Joan de Déu, Barcelona, Spain
CIBERER-Instituto de Salud Carlos III, Barcelona, Spain
Green Submitted, gold
|